Compare GLBS & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | DYAI |
|---|---|---|
| Founded | 2006 | 1979 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 29.9M |
| IPO Year | 2007 | 2004 |
| Metric | GLBS | DYAI |
|---|---|---|
| Price | $1.57 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | $3.00 |
| AVG Volume (30 Days) | 33.6K | ★ 35.0K |
| Earning Date | 03-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,444,000.00 | $3,342,195.00 |
| Revenue This Year | $24.03 | $12.52 |
| Revenue Next Year | $13.92 | $92.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.49 | N/A |
| 52 Week Low | $0.99 | $0.71 |
| 52 Week High | $1.99 | $1.73 |
| Indicator | GLBS | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 37.51 |
| Support Level | $1.65 | $0.80 |
| Resistance Level | $1.67 | $0.92 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 16.00 | 20.23 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.